Contact

PAXMAN publishes its year-end report for 2022

Paxman’s strongest year to date

October–December 2022
The Group’s total sales amounted to 40.7 (29.3) MSEK for the period October–December, an increase of 39%. The revenues in the US have seen a growth rate of 21% compared to Q4 2021.
The EBITDA for Q4 amounted to 12.8 (4.2) MSEK, and for the same period the PAXMAN Group achieved a negative net result of -9.8 MSEK (-1.3 MSEK). Included within the financial costs is a currency loss of -16.8 MSEK in Q4 2022 compared to a loss of -1.2 MSEK in Q4 2021.
The corresponding earnings per share were -0.51 (-0.07) SEK. Cash flow before financing activities totalled -7.8 (-4.7) MSEK for the period October–December, of which investments in fixed assets -6.8 (-5.8) MSEK.

January–December 2022
Total 2022 sales were 145.9 (96.2) MSEK. EBITDA amounted to 16.2 (2.8) MSEK. Net result for the year reached -10.3 (-12.8) MSEK, and earnings per share were -0.54 (-0.73) SEK. Cash flow before financing activities totalled -34.0 (-28.6) MSEK, of which investments in fixed assets -35.7 (-23.8) MSEK.

In 2022 a total of 528 scalp cooling systems were installed around the world, with an additional 217 systems in the order book as of 23 February 2023.

Significant developments in Q4

  • In November, Paxman announced that the company has been selected by the SWOG Cancer Research Network, an independent global cancer research community that designs and conducts publicly funded clinical trials, for the Paxman Limb Cryocompression System (PLCS) to be used in a prospectively designed study looking at prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN).
  • In November, Paxman announced that the US Centers for Medicare & Medicaid Services (CMS) has published the final rule, which revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for Calendar Year (CY) 2023
  • At the end of the quarter Paxman AB announced that it has retained Arrowhead Business and Investment Decisions, LLC. (“Arrowhead”) to provide investor relations services to the Company and develop its international market awareness. Arrowhead will advise Paxman on its international capital markets strategy and has been engaged to, among other matters, expand the involvement of the investment community.

Significant developments after year-end

  • In January the company announced that it has received EU Medical Device Regulation (MDR) certification from its Notified Body, the British Standards Institution (BSI). Paxman is amongst the latest companies to achieve MDR approval, reaffirming its commitment to the market, its customers and, most importantly, the patients who will continue to benefit from the use of the Paxman Scalp Cooling System.
Paxman Q4 2022 ENG Paxman Q4 2022 ENG
What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram